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DOI 10.1016/j.ccr.2011.02.006SUMMARYTumor-associated macrophages (TAMs) can influence cancer progression and metastasis, but the mecha-
nism remains unclear. Here, we show that breast TAMs abundantly produce CCL18, and its expression in
blood or cancer stroma is associatedwithmetastasis and reduced patient survival. CCL18 released by breast
TAMs promotes the invasiveness of cancer cells by triggering integrin clustering and enhancing their adher-
ence to extracellular matrix. Furthermore, we identify PITPNM3 as a functional receptor for CCL18 that medi-
ates CCL18 effect and activates intracellular calcium signaling. CCL18 promotes the invasion andmetastasis
of breast cancer xenografts, whereas suppressing PITPNM3 abrogates these effects. These findings indicate
that CCL18 derived from TAMs plays a critical role in promoting breast cancer metastasis via its receptor,
PITPNM3.INTRODUCTION
The tumor microenvironment comprises a variety of nonmalig-
nant stromal cells that play a pivotal role in tumor progression
and metastasis (Robinson et al., 2009). Among them, tumor-
associated macrophages (TAMs) are the most notable migratory
hematopoietic cell type (Mantovani and Sica, 2010; Solinas et al.,
2009). Evidence from clinical and epidemiological studies has
shown a strong association between TAM density and poor
prognosis in several types of cancer (Condeelis and Pollard,
2006; Pollard, 2004), including breast cancer (Mantovani et al.,
2007).
Macrophages are heterogeneous cells that respond differently
to various microenvironmental signals and, thus, display distinct
functions (Gordon, 2003; Martinez et al., 2009). Breast TAMs are
primarily a macrophage subpopulation with M2 phenotype acti-
vated by interleukin-4 (IL-4) produced by CD4+ T cells (DeNardoSignificance
The infiltration level of tumor-associated macrophages (TAMs
cancer, but the underlying mechanisms were not clear. Throu
that CCL18 is abundantly expressed, and the CCL18 level in
patients with breast cancer. CCL18 is critical for breast TAMs t
We identify PITPNM3 as a functional receptor for CCL18 in pro
tant TAM-derived cytokine in promoting breast cancer metasta
to the activation of intracellular calcium signaling and enhanceet al., 2009). Further mechanistic studies reveal that TAMs
promote breast cancer progression and metastasis by releasing
a variety of cytokines, including chemokines, inflammatory
factors, and growth factors (Condeelis and Pollard, 2006;
Gocheva et al., 2010). TAM-derived cytokines may promote
the invasiveness of tumor cells by enhancing their adhesion to
extracellular matrix (ECM) in the tumor stroma (Pittet, 2009).
Previous studies have identified several factors important for
TAM-promoted tumor progression, including EGF, VEGF, and
MMP7/9 (Coussens et al., 2000; Dirkx et al., 2006; Goswami
et al., 2005; Leek et al., 2002). However, these factors are also
produced by cancer cells themselves, and such autocrine
signaling also contributes to cancer development (Lichtenberger
et al., 2010). Currently, the cytokine profile of TAMs remains
largely unknown, and it is unclear whether there are some exclu-
sively TAM-derived cytokines that are functionally essential to
tumor progression.) is associated with poor prognosis in patients with breast
gh the analysis of cytokine profile of breast TAMs, we find
blood or cancer stroma is associated with metastasis of
o promote the migration and invasion of breast cancer cells.
moting metastasis. Our study shows that CCL18 is an impor-
sis and suggests that CCL18-PITPNM3 interaction is crucial
d invasiveness of breast cancer cells.
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Figure 1. Breast TAMs Constitutively Express CCL18
(A) The ratio of a panel of cytokine mRNA in TAMs versus PBMs from patients with breast cancer and IL-4-activated MDMs versus unactivated MDMs from
healthy donors, as assayed by qRT-PCR.
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CCL18 from TAM Promotes Breast Cancer MetastasisChemokine (C-C motif) ligand 18 (CCL18) is a chemokine
predominantly produced by monocyte-derived cells with M2
phenotype (Kodelja et al., 1998). Excessive production of
CCL18 in M2 macrophages was demonstrated in various
chronic inflammations and fibrotic diseases, including
Gaucher’s disease and rheumatoid arthritis (Martinez et al.,
2009; Schutyser et al., 2005). In addition, constitutive expression
of CCL18 was observed in macrophages infiltrating ovarian
cancer, gastric cancer, and glioma (Chang et al., 2010; Leung
et al., 2004; Schutyser et al., 2002; Zohny and Fayed, 2010).
However, the role of CCL18 in cancer progression is controver-
sial. CCL18 was reported to participate in immunosuppression
of ovarian cancer (Duluc et al., 2009; Zohny and Fayed, 2010)
but was associated with prolonged survival in patients with
gastric cancer (Leung et al., 2004). Although M2 macrophages
are abundant in breast cancer stroma, the role of CCL18 in
breast tumor progression remains elusive. Furthermore, under-
standing of CCL18 function is hampered by the fact that
CCL18 receptor and the underlying pathways remain unknown.
In this study we aimed to investigate the contribution of CCL18 in
breast cancer metastasis and to identify the receptor and
signaling pathway that mediate CCL18 effects.
RESULTS
CCL18 Expression in Breast TAMs Correlates
with Tumor Invasiveness
Because breast TAMs are primarily M2 macrophages activated
by Th2 cytokines, most notably IL-4 (DeNardo et al., 2009), we
performed quantitative RT-PCR (qRT-PCR) to screen a panel
of cytokines related to M2 macrophages (Gordon, 2003) in
paired TAM and peripheral blood monocyte (PBM) samples
isolated from six patients with invasive ductal breast carci-
nomas, and in IL-4-treated versus untreated monocyte-derived
macrophages (MDMs) obtained from six healthy donors. The
mRNA profile of M2-related cytokines in TAMs was analogous
to that in IL-4-activated MDMs. Among all the cytokines tested,
CCL18 is the most abundantly expressed cytokine in both TAMs
and IL-4-activated M2 cells (Figure 1A).
To confirmCCL18 expression in breast TAMs, we examined the
mRNAandprotein expressionof thechemokine inpairedTAMand
PBMsamples isolated fromanother set of33patientswith invasive
breast carcinomas. Examined by qRT-PCR, CCL18 mRNA was
25 ± 17-fold higher in TAMs than PBMs in 14 patients with breast
cancer without regional lymph node metastasis, whereas it was
91 ± 52-fold higher in the other 19 patients with axillary lymph
node metastasis (Figure 1B; p < 0.0001). Western blotting also
showed that CCL18 protein was only identified in TAMs, but not
in PBMs, of patients with breast cancer, and its expression was(B) The ratio of CCL18 mRNA in TAMs versus PBMs from patients with breast ca
qRT-PCR (left). Each bar corresponds to mean ± standard deviation (SD) of eac
PBMs from patients with breast cancer with or without axillary lymph node meta
(C) Immunohistochemical staining of CCL18 in benign cystic fibrosis of the breast
(D) Serum CCL18 level in the patients with benign breast diseases and invasive
determined by ELISA. Bars correspond to mean ± SD.
(E) Kaplan-Meier survival curve of patients with breast cancer with lower (%20 pe
field, n = 157; p < 0.001) with a median follow-up period of 45 months. The numb
graph.
See also Figure S1.much stronger in the patients with axillary lymph nodemetastasis
than thosewithoutmetastasis (Figure1B). Likewise,CCL18mRNA
and protein were dramatically upregulated in IL-4-activated M2
cells, whereas only slightly elevated in LPS-activated M1 cells,
but were not detected in unactivated MDMs, or MDA-MB-231
cells, a breast cancer line with metastasis potential, or MCF-10A,
an immortalized breast epithelial line (see Figures S1A and S1B
available online). Furthermore, IL-4-activated M2 cells produced
abundant amount of CCL18 protein in their supernatants deter-
mined by ELISA (Figure S1E). The specificity of CCL18 expression
and production in IL-4-activatedM2cells was confirmed by trans-
fecting the cells with small interfering RNAs (siRNAs) targeting
CCL18 mRNA (Figures S1C and S1D).
Immunohistochemistry for CCL18 expression in breast cancer
tissues revealed that CCL18-positive cells were observed scat-
tered in the tumor stroma of 505 out of 562 cases of invasive
breast carcinomas (Figure 1C). However, no staining was
observed in the neoplastic cells and the adjacent non-neoplastic
epithelia. Additionally, CCL18+ cells were absent in all benign
breast tissues, including fibrocystic lesions with or without atyp-
ical epithelial hyperplasia, whereas they were occasionally iden-
tified in the stroma of 11 out of 57 cases of ductal carcinomas
in situ (DCIS) of the breast (Figure 1C). Furthermore, confocal
microscopy revealed colocalization of CCL18 and CD68 immu-
nostaining, a marker for macrophages, in breast cancer tissues,
confirming that CCL18 immunostaining cells were subsets of
macrophages (Figure S1F).
We next correlated CCL18+ TAM counts with the clinicopath-
ological status of patients with breast cancer (Table 1). The
number of CCL18+ TAMs increased with higher tumor burden
defined by tumor size (p = 0.044) and staging (p < 0.001), and
aggressive tumor biology by advanced histopathological
grading (p = 0.002) and lymphovascular invasion (LVI;
p < 0.001). However, there was no observed difference in
CCL18+ TAM counts according to estrogen receptor (ER) status
(p = 0.31). Yet, CCL18+ TAMs increased with CD4+ lymphocytic
infiltration in cancer stromas (p = 0.036; Figure S1G). Addition-
ally, CCL18+ TAMs were more abundant in the primary tumors
with axillary lymph node (p < 0.01) and distal metastasis
(p = 0.014) but was unrelated to the proliferation of cancer cells,
determined by Ki67 and PCNA expression (p > 0.05; Table S2).
CCL18 protein level in the serum of patients with breast cancer
with lymph node or distal metastasis was also significantly higher
than those without metastasis (Figure 1D; p < 0.001). Consistent
results were obtained when a different cutoff of CCL18+ TAM
counts was applied (Table S1). These data imply that CCL18
produced by TAMs correlates with the invasiveness but not the
growth kinetics of breast tumor cells. However, CCL18 + macro-
phage counts in the primary breast tumors were much higherncer (n = 33) with or without axillary lymph node metastasis, as determined by
h individual patient. Representative western blotting for CCL18 in TAMs and
stasis (right). b-Actin was used as a loading control.
, atypical hyperplasia, breast carcinoma in situ, and invasive breast carcinoma.
breast carcinomas with or without axillary lymph node or distal metastasis, as
r view of field, n = 405) and higher CCL18-positive TAM counts (>20 per view of
er of survived patients stratified to the follow-up periods is indicated below the
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Table 1. Correlation of CCL18 Expressing TAMCounts with Clini-
copathological Status in 562 Cases of Patients with Breast Cancer
CCL18+ TAM Counts %5 6–20 >20 p Value
Age (years)
%45 126 75 69
>45 106 99 87 0.716
Tumor Size (cm)
%2 126 75 69
>2 106 98 88 0.044
Stage
0 46 10 1
I 73 13 1
II 107 97 92
III 6 53 63 <0.001
Histological Gradea
I 45 46 17
II 72 60 64
III 69 57 75 0.002
Metastasisb
Lung 2 4 7
Liver 0 13 12
Bone 4 25 27
Brain 1 3 7 0.014
Lymph Node Metastasis
0 165 33 17
1–3 58 84 70
R4 9 56 70 <0.01
LVI
(+) 32 61 91
() 200 112 66 <0.001
ER
(+) 162 129 120
() 70 44 37 0.31
Her2
(+) 34 25 41
() 197 147 117 0.007
CCL5
() 59 44 45
(+) 61 53 39
(++) 68 47 35
(+++) 44 28 39 0.364
CD4+ T Lymphocytesc
Low 90 58 46
Media 88 57 53
High 54 58 58 0.036
CD8+ T Lymphocytesc
Low 85 49 55
Media 74 66 58
High 73 57 45 0.414
See also Tables S1–S3.
aGrading in 505 cases of invasive ductal carcinoma.
bDistant metastasis identified during postoperative follow-up.
c Percent volume of CD4+/CD8+ T lymphocytes.
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liver, lung, and brain (Figure S1H), suggesting that CCL18
producedbyTAMsprobably affects the primary tumors in a para-
crine manner.
Kaplan-Meier survival curve with a median follow-up period of
45 months demonstrated that patients with low CCL18+ TAM
count (%20), as defined elsewhere (Leung et al., 2004), survive
significantly longer than those with high CCL18+ cell counts
(>20) (Figure 1E; p < 0.001). In amultivariate Cox regression anal-
ysis, CCL18+ TAMcount was associatedwith poor survival prog-
nosis of patients with breast cancer (hazard ratio, 1.47;
p = 0.022), independent of other clinical covariates (Table S3),
indicating that CCL18 is an independent prognostic factor for
breast cancer. However, our cohort did not show any significant
correlation of patient prognosis with ER expression or LVI.
TAMs and IL-4-Activated MDMs Promote
the Invasiveness of Breast Cancer Cells via CCL18
Boyden chambers were used to examine the invasiveness of
breast cancer cells by plating them on fibronectin-coated inserts
with macrophages in the lower wells. Compared with MDA-MB-
231 cells in medium alone, the number of invading cancer cells
upon coculturing for 8 hr with resting or LPS-activated MDMs
increased by 66% (p < 0.05) and 2-fold (p < 0.01), respectively,
and more dramatically by nearly 11-fold with IL-4-activated
MDMs (p < 0.001; Figure 2A). The direct influence of LPS and
IL-4 on the invasiveness of cancer cells was ruled out by adding
these mediators alone in the lower chambers (data not shown).
Similarly, the invasiveness of MDA-MB-231 cells and primary
breast cancer cells was enhanced by 6- and 9-fold, respectively,
upon coculturing with TAMs isolated from primary breast tumor
samples, whereas only by 2- and 3-fold, respectively, with the
macrophages derived from PBMs of the same patients (Fig-
ure 2B). Thus, mediators released by TAMs or IL-4-activated
MDMs promote the invasiveness of breast cancer cells in vitro.
To determine whether CCL18 contributes to cancer cell inva-
sion, we employed a polyclonal anti-CCL18 antibody that was
shown by R&D Systems to neutralize CCL18 function in lympho-
cytes, as well as the two CCL18-siRNAs. In the presence of LPS-
or IL-4-activated macrophages, the number of invasive cancer
cells was reduced by 27% and 53%, respectively, by adding
anti-CCL18 antibody at 5 mg/ml, and by 40% and 73%, respec-
tively, at 10 mg/ml, but not by an isotype-matched IgG at
10 mg/ml (Figure 2A). However, anti-CCL18 antibody itself did
not influence the invasion of cancer cells in culturemedium alone
or cocultured with unactivatedmacrophages that do not express
CCL18 (Figure 2A). Addition of anti-CCL18 antibody to the cocul-
ture system of primary TAMs with MDA-MB-231 line or primary
breast cancer cells also reduced the number of invasive cancer
cells in a dose-dependent manner (Figure 2B; p < 0.01). Trans-
fection of IL-4-activated MDMs with either of the two
CCL18-siRNAs also reduced the number of invasive cancer cells
by 75% and 70%, respectively (Figure 2C). Furthermore, treat-
ment of MDA-MB-231 and SKBR3 line with recombinant
CCL18 (rCCL18, 0–20 ng/ml) for 8 hr enhanced the invasion of
cancer cells in a dose-dependent manner, whereas treatment
of 20 ng/ml rCCL20, a member from the same chemokine family,
had no effect (Figure 2D; Figure S2D). However, incubation of
MDA-MB-231 cells with rCCL18 at 20 ng/ml for up to 24 hr did
Figure 2. Breast TAMs and IL-4-Activated MDMs Promote the Invasion of Breast Cancer Cells via CCL18
(A) Boyden chamber assay for MDA-MB-231 cells plated on the upper cell culture inserts, with culture medium alone (Med), unactivated (Ua), LPS-activated (M1),
or IL-4-activated MDMs (M2) plated in the lower chambers in the presence or absence of an anti-CCL18 antibody at 5 or 10 mg/ml, or an isotype-matched IgG
control (IgG).
(B) Similar to (A), MDA-MB-231 cells or primary breast cancer cells were cocultured with PBMs or TAMs from patients with breast cancer plated.
(C) Similar to (A), MDA-MB-231 cells were cocultured with unactivated (Ua) MDMs or IL-4-activated MDMs (M2) that were untreated (Un), mock transfected,
or transfected with either of the two CCL18-siRNAs or GFP-siRNA.
(D) Boyden chamber assay for MDA-MB-231 cells with rCCL18 at increasing concentrations (1–20 ng/ml) or rCCL20 at 20 ng/ml added to culture medium in the
lower chambers. Bars correspond to mean ± SD. **p < 0.01 and ***p < 0.001 as compared with the cells treated with medium alone, whereas ## p < 0.01 as
compared with the untreated cells cocultured with M2 MDMs or TAMs.
See also Figure S2.
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CCL18 from TAM Promotes Breast Cancer Metastasisnot influence cancer cell proliferation, determined by BrdU stain-
ing, soft agar assay, and [3H]incorporation assay (Figures S2A–
S2C). Collectively, these data suggest that both IL-4-activated
macrophages and TAMs promote the invasiveness of breast
cancer cells via CCL18.CCL18 Enhances ECM Adherence and Migration
of Breast Cancer Cells
To explore the mechanism that CCL18 promotes invasion,
we investigated whether CCL18+ macrophages induce the
adherence of breast cancer cells to fibronectin, the mostCancer Cell 19, 541–555, April 12, 2011 ª2011 Elsevier Inc. 545
Figure 3. IL-4-Activated MDMs Promote Fibronectin Adherence and Migration of Breast Cancer Cells via CCL18
(A) Adherence assays for MDA-MB-231 cells suspended in serum-freemedium in the lower wells of the Boyden chambers coatedwith fibronectin, with or without
(Med) unactivated (Ua) or IL-4-activated MDMs (M2) plated on the inserts in the presence or absence of an anti-CCL18 antibody at 5 mg/ml (Ab5) or 10 mg/ml
(Ab10), or an isotype-matched IgG control (IgG).
(B) Similar to (A), MDA-MB-231 cells were cocultured with unactivated (Ua) or IL-4-activated MDMs (M2) that were untransfected (Un), mock transfected, or
transfected with either of the two CCL18-siRNAs (si1 and si2) or GFP-siRNA.
(C) MDA-MB-231 cells were suspended in serum-free medium and allowed to adhere to culture plate coated with fibronectin in the presence or absence of
rCCL18 and rCCL20 at increasing concentrations (1–20 ng/ml). Bars correspond tomean ± SD. **p < 0.01 and ***p < 0.001 as comparedwith the cells treatedwith
medium alone, whereas ## p < 0.01 as compared with the untreated cells cocultured with M2 MDMs.
(D) Wound-healing assay for MDA-MB-231 cells plated in the lower Boyden chambers, with unactivated (Ua) or IL-4-activated MDMs (M2) seeded on cell culture
inserts in the presence or absence (Un) of an anti-CCL18 antibody at 5 mg/ml (Ab5) or 10 mg/ml (Ab10), or an isotype-matched IgG control (IgG).
(E) Wound-healing assay for MDA-MB-231 cells in the presence or absence of rCCL18 at increasing concentration (1–20 ng/ml) or rCCL20 at 20 ng/ml.
See also Figure S3.
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(Simpson-Haidaris and Rybarczyk, 2001). In a Boyden chamber
where macrophages were plated on the 0.4 mm cell culture
inserts, cancer cells were suspended in serum-free media in
the lower wells coated with fibronectin. After 60min of coculture,
IL-4-activated MDMs dramatically increased the number of
cancer cells adherent to fibronectin as compared with unacti-
vated MDMs or culture medium alone, which was blocked by
the anti-CCL18 antibody in a dose-dependent manner
(Figure 3A; p < 0.01). Consistent with the finding above, IL-4-acti-
vated MDMs transfected with CCL18-siRNA significantly lost
their ability to promote the adherence of cancer cells to fibro-
nectin (Figure 3B; p < 0.01). Moreover, treatment of sus-
pended MDA-MB-231 cells with rCCL18 for 60 min enhanced546 Cancer Cell 19, 541–555, April 12, 2011 ª2011 Elsevier Inc.their adherence to fibronectin in a dose-dependent manner
(Figure 3C).
Wound-healing assay was used to evaluate the effect of
CCL18+ macrophages on cancer cell migration, another hall-
mark contributing to the invasion and metastasis of cancers.
MDA-MB-231 cells were plated in the lower wells of Boyden
chamber and cocultured for 12 hr with macrophages that were
seeded on 0.4 mm inserts, allowing only cytokine but not cellular
communication between the upper and lower chambers. Cancer
cells that were exposed to IL-4-activated MDMs migrated more
rapidly to close the scratched wounds compared with those
exposed to resting MDMs or culture media alone. Addition of
anti-CCL18 antibody inhibited the effect of IL-4-activated
MDMs on cancer cell migration in a dose-dependent manner
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or SKBR3 cells with rCCL18 (0–20 ng/ml) dose dependently
promoted the migration of cancer cells (Figure 3E; Figure S3B).
These results indicate that CCL18 is critical for TAMs to promote
ECM adherence and migration of breast cancer cells.
PITPNM3 Is a Transmembrane Receptor for CCL18
Activities
To evaluate whether a potential receptor for CCL18 exists at the
breast cancer cell membrane, MDA-MB-231 cells were incu-
bated with rCCL18 for 3 hr at 4C, fixed, and then stained with
an Alexa 488-labeled anti-CCL18 antibody. Immunofluores-
cence showed that CCL18 was localized to cell membrane (Fig-
ure 4A), implying that specific molecules on the cancer cell
surface may mediate the biological effects of CCL18. Addition
of the anti-CCL18 antibody during incubation prevented
CCL18 localization to cell membrane (Figure S4A), validating
its neutralizing function in breast cancer cells.
To identify the unknown receptor of CCL18 function, the
membranous proteins of rCCL18-treated MDA-MB-231 cells
were extracted, immunoprecipitated with a monoclonal anti-
CCL18 antibody that has no neutralizing function, and resolved
on a denaturing gel. A specific protein band was revealed by
Coomassie blue staining in the resultant immunoprecipitate
(lane 7, Figure 4B) and analyzed by liquid chromatography-
mass spectrometry. The protein band was identified to be
a membrane-associated phosphatidylinositol transfer protein
3, PITPNM3 (also named PYK2 N-terminal domain-interacting
receptor 1, Nir1), a human homolog of the Drosophila retinal
degeneration B (rdgB) (Figure 4C). This was further confirmed
by immunoblotting of the immunoprecipitate with an anti-
PITPNM3 antibody (Figure 4D). Immunohistochemistry showed
much stronger staining of PITPNM3 in the cancer cell membrane
and cytoplasm of all 192 cases of breast cancers on tissue arrays
(Figure S4B) and 535 out of 562 cases on paraffin tissue sections
(Table S1) than in the benign breast epithelia of 33 cases of fibro-
cystic disease (Figure 4E). PITPNM3 immunostaining in breast
cancers was independent of CCL18+ TAM counts (p > 0.05;
Table S2). Interestingly, PITPNM3 expression was nearly absent
in 83 cases of gastric cancers (Figure 4E; Figure S4B), implying
that the two malignancies may respond distinctly to CCL18.
This was further confirmed by western blot showing that
PITPNM3 expression was much stronger in three breast cancer
lines, including ER+ MCF-7, Her2+ BT-474, and triple-negative
MDA-MB-231, than that in the immortalized MCF-10A breast
epithelial line, but was barely detectable in two gastric cancer
lines (Figure 4F).
To further confirm whether CCL18 colocalizes with PITPNM3
on breast cancer cell membrane, we incubated MDA-MB-231
cells with rCCL18 at 4C for 3 hr. Confocal microscopy using
fluorescence-labeled antibodies for CCL18 and PITPNM3
demonstrated that CCL18 colocalizes with PITPNM3 on the
plasma membrane of MDA-MB-231 cells (Figure 4G). RNAi-
mediated silencing of PITPNM3 expression in MDA-MB-231
cells (Figure S4C) efficiently abrogated CCL18 localization on
the cell surface (Figure 4G), suggesting that CCL18 interacts
with PITPNM3 at the plasma membrane of breast cancer cells.
Because PITPNM3 can be phosphorylated at its intracellular
tyrosine residue (Lev et al., 1999), we investigated whetherCCL18 might induce tyrosine phosphorylation of PITPNM3 by
immunoprecipitating the membrane proteins extracted from
rCCL18-treated MDA-MB-231 or MCF-10A cells with anti-
PITPNM3. Immunoblot analysis of the immunoprecipitates using
antibodies for phosphotyrosine and PITPNM3, respectively,
demonstrated that rCCL18 dose dependently induced tyrosine
phosphorylation of PITPNM3, whereas total PITPNM3 protein
expression remained unchanged (Figures S4D and S4E).
To verify whether PITPNM3 is a functional receptor for CCL18,
we created stable HEK293 lines expressing PITPNM3 (Fig-
ure S5A). Flow cytometry using an anti-PITPNM3 antibody
demonstrated PITPNM3 localization at the cell surface of non-
permeabilized stable PITPNM3 transfectants and MDA-MB-
231 cells (Figure S5B). To provide a more refined assessment
for PITPNM3 localization, we performed confocal microscopy
for immunofluorescent staining of the protein in the stable trans-
fectants and MDA-MB-231 cells that were costained with
subcellular compartment trackers, and found that PITPNM3
primarily localized to the plasmamembrane, but not to the endo-
plasmic reticulum or Golgi apparatus (Figure S5C). These results
were further confirmed by western blot analysis of the PITPNM3
immunoprecipitates from the fractionated plasma and intracel-
lular membranes (Figures S5D and S5E). We next measured
the intracellular calcium ([Ca2+]i) changes upon CCL18 stimula-
tion using calcium mobilization assay, which has been
commonly used to measure chemokine receptor activation
(Murdoch and Finn, 2000). PITPNM3 transfectants responded
to rCCL18, but not to rCCL20, in a dose-dependant manner
with an optimal concentration of 40 ng/ml, but transfectants
with vector alone or nontransfected cells did not respond to
the rCCL18 (Figure 5A; Figure S5F). Along with [Ca2+]i changes,
western blot analysis demonstrated that rCCL18 induced phos-
phorylation of PLCg1 and PKCz and increased the level of
IP3KB, which are known mediators in the [Ca2+] signaling
pathway (Figure 5B). To directly evaluate the ability of CCL18
to bind to PITPNM3, radioligand binding assays were performed.
Because the parental 293 cells or cells transfected with vector
alone did not bind to 125I-CCL18 (data not shown), PITPNM3
transfectants showed a high level of specific binding for
125I-CCL18, which could be competed by unlabeled CCL18
(Kd = 5.17 nM, 3.30–7.04 nM, 95% confidence interval; Fig-
ure 5C). Unlabeled CCL3 and CCL4 that show sequence
homology to CCL18 by 64% and 48%, respectively (Schutyser
et al., 2005), also competed for 125I-CCL18 binding with much
less affinity (Kd = 276.7 nM for CCL3, and Kd = 833 nM for
CCL4), whereas CCL2 (35% homology) and CCL20 (28%
homology) (Schutyser et al., 2005) had no apparent effect (Fig-
ure 5C). Specific binding of CCL18 to PITPNM3 on the surface
of PITPNM3 transfectants could be further visualized by their
costaining under confocal microscopy (Figure 5D). Next, we
tested the ability of CCL18 to induce directional migration of
PITPNM3 transfectants. As shown in Figure 5E, rCCL18, but
not rCCL20, induced significant migration of PITPNM3 transfec-
tants in a dose-dependent manner in vitro, whereas chemotaxis
of the parental 293 cells and the cells transfected with vector
alone was not affected by CCL18. In contrast, adding rCCL18
into the upper wells of the chemotaxis chambers at increasing
concentrations dose dependently attenuated migration of the
PITPNM3 transfectants in response to rCCL18 in the lower wellsCancer Cell 19, 541–555, April 12, 2011 ª2011 Elsevier Inc. 547
Figure 4. CCL18 Binds to PITPNM3 on Breast Cancer Cell Membrane
(A) Confocal microscopy for MDA-MB-231 cells treated with PBS, rCCL20, or rCCL18 at 20 ng/ml at 4C, then fixed and stained with an Alexa 488-labeled
anti-CCL18 antibody. An isotype-matched IgG (IgG) was used as a control, and cell nuclei were counterstained with DAPI.
(B) Immunoprecipitation of the membrane extracts (ME) from rCCL18-treatedMDA-MB-231 cells with anti-CCL18 antibody. Lane 1 shows input of ME (5%), lane
2 flowthrough (5%), lane 3 ME from the PBS-treated cells incubated with uncoupled protein A/G beads, lane 4 ME from rCCL18-treated cells incubated with
uncoupled beads, lane 5 ME from PBS-treated cells incubated with antibody-coupled beads, lane 6 SDS-treated ME from rCCL18-treated cells incubated with
antibody-coupled beads, and lane 7 ME from rCCL18-treated cells incubated with antibody-coupled beads. IgG HC, IgG heavy chain; IgG LC, IgG light chain.
(C) Mass spectra of a representative peptide fragment from the protein band indicated by an arrow in lane 7 of (B).
(D) Western blot validation of mass spectrometric identification using an anti-PITPNM3 antibody (upper) and an anti-CCL18 antibody (lower). All lanes and
conditions are described as in (B).
(E) Immunohistochemistry for PITPNM3 expression in breast and gastric carcinomas, as well as normal breast and gastric tissues in paraffin tissue sections.
(F) Western blotting for PITPNM3 expression in gastric cancer cell lines of SGC7901 and SNU16, breast epithelial MCF-10A line, and breast cancer cell lines
of MCF-7, BT-474, and MDA-MB-231. b-Actin was used as a loading control.
(G) Confocal microscopy for MDA-MB-231 cells stained with an Alexa 488-labeled anti-CCL18 antibody and a Cy3-labeled anti-PITPNM3 antibody. The cells
were treated with PBS (row 1) or recombinant CCL18 (rCCL18) at 20 ng/ml (rows 2–6) for 3 hr at 4C, and were untransfected (row 2), mock transfected (row 3),
transfected with GFP-siRNA (row 4), or either of the two PITPNM3-siRNAs (rows 5 and 6). Cell nuclei were counterstained with DAPI.
See also Figure S4.
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stimulated calcium signaling, and induced directional migration
of the 293 cells with ectopic PITPNM3 expression, suggesting
that PITPNM3 is a functional receptor for the chemokine.548 Cancer Cell 19, 541–555, April 12, 2011 ª2011 Elsevier Inc.PITPNM3 Mediates CCL18-Induced ECM Adherence
and Invasion of Breast Cancer Cells
To further investigate the pathophysiological relevance of
the CCL18-PITPNM3 interaction in breast cancer cells, we
Figure 5. CCL18 Induces Functional Response in PITPNM3 Expressing HEK293 Cells
(A) Mobilization of [Ca2+]i in HEK293 cells that were stably transfected with pcDNA3-PITPNM3 (PITPNM3), pcDNA3 vector alone (vector), or untransfected and
were treated with HBSS, rCCL18, or rCCL20 at 40 ng/ml.
(B) Western blotting for the phosphorylated and total proteins of PLCg1, PKCz, and IP3KB in HEK293 cells that were transfected or treated as in (A). Thapsigargin
(TG), a calcium channel agonist, was used as a positive control for calcium signaling.
(C) Binding assaywith 60,000 cpm of 125I-CCL18 in the presence or absence of increasing concentrations of unlabeled rCCL3, rCCL4, rCCL2, rCCL18, or rCCL20
for HEK293 cells that were transfected as in (A).
(D) Confocal microscopy for HEK293 cells stained with an Alexa 488-labeled anti-CCL18 antibody and a Cy3-labeled PITPNM3 antibody. The cells were
transfected as in (A) and treated with PBS or rCCL18 at 40 ng/ml.
(E and F) Boyden chamber assays for HEK293 cells transfected as in (A) and treated with increasing concentrations of rCCL18 or rCCL20 at 40 ng/ml added to
culture medium in the lower chambers (E), or added to culture medium in the upper chambers in the presence of rCCL18 at 20 ng/ml in the lower ones (F). Bars
correspond to mean ± SD. **p < 0.01 and ***p < 0.001 as compared with the cells treated in the absence of rCCL18 in the lower (E) or the upper (F) chambers.
See also Figure S5.
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CCL18 from TAM Promotes Breast Cancer Metastasisexamined whether silencing of PITPNM3 influenced the biolog-
ical effects of CCL18 on breast cancer cells. In the presence of
rCCL18, transfection with either of the PITPNM3-siRNAs
efficiently inhibited the adherence of MDA-MB-231 cells to fibro-
nectin (p < 0.001; Figure 6A) and significantly reduced their inva-
siveness (p < 0.001; Figure 6B) to the level comparable to the
cells without rCCL18 treatment (p > 0.05; Figures 6A and 6B).
Transfection with PITPNM3-siRNA alone without rCCL18
treatment did not influence the adherence of MDA-MB-231 cells
to fibronectin (p > 0.05; Figure 6A) or their invasiveness (p > 0.05;
Figure 6B). These results suggest that the biological activities of
CCL18 to promote invasiveness of breast cancer cells are
PITPNM3 dependent.
Because PITPNM3 phosphorylation is associated with activa-
tion of proline-rich tyrosine kinase 2 (Pyk2) (Lev et al., 1999), one
of the nonreceptor protein tyrosine kinases (NPTKs) at the focal
adhesion complex (FAC), we examined whether CCL18 induced
ECM adherence of the tumor cells via activating components of
the FAC. Upon stimulation with rCCL18, phosphorylation of Pyk2
at Tyr402, Src at Tyr416, and FAK at Tyr397 was markedly
induced in MDA-MB-231 cells, whereas the total protein levels
remained unchanged (Figure 6C). However, transfection with
PITPNM3-siRNA abrogated phosphorylation of the aforemen-
tioned NTPKs in MDA-MB-231 cells exposed to rCCL18 (Fig-
ure 6C), suggesting that CCL18 activates the NPTKs at the
FAC of breast cancer cells by interacting with PITPNM3.
NPTK activation at the FAC may enhance ECM adherence of
cancer cells via integrin clustering. Confocal microscopy of
immunofluorescent staining with an anti-integrin a5b1 antibody
demonstrated prominent integrin clustering on the membrane
of MDA-MB-231 cells treated with rCCL18 (Figure 6D). Abolition
of FAK phosphorylation by RNAi-mediated silencing of PITPNM3
(Figure 6C) or FAK itself (Figure S6A) efficiently inhibited
CCL18-induced integrin b1 clustering (Figure 6E) without altering
the integrin expression (Figure S6A), which leads to tremendous
reduction in fibronectin adherence of MDA-MB-231 cells (Fig-
ure 6F). Additionally, silencing integrin b1 (Figure S6B) in the
presence of CCL18 prevented their own clustering (Figure 6E)
and fibronectin adherence of the tumor cells (Figure 6F) but did
not affect total FAK expression or FAK phosphorylation (Fig-
ure S6B), suggesting that FAK activation induced by CCL18-
PITPNM3 interaction is independent of integrin b1 signaling.
More importantly, abrogation of integrin clustering or fibronectin
adherence by FAK-siRNA or integrin-b1-siRNA significantly
reduced the invasion of MDA-MB-231 cells in Boyden chambers
(Figure 6G). Collectively, these data suggest that integrin clus-
tering and fibronectin adherence mediated by FAK activation
due to CCL18-PITPNM3 interaction contribute to the overall
process of CCL18-induced invasion in the breast cancer cells.
CCL18 Enhances Invasion and Metastasis
of Breast Cancers In Vivo
To examine the effect of CCL18-PITPNM3 interaction on breast
cancer invasion and metastasis in vivo, we inoculated BT-474
cells (low metastasis potential) and MDA-MB-231 cells (high
metastasis potential) into the mammary fat pads of NOD/SCID
mice, and evaluated cancer metastasis to the lungs and livers
when xenografts reached 1.5 cm in diameter. Intratumor
injection of rCCL18 at a dosage of 0.1 mg/kg biweekly for550 Cancer Cell 19, 541–555, April 12, 2011 ª2011 Elsevier Inc.4 consecutive weeks, but not PBS or rCCL20 at the same
dosage, enhanced vascular invasion and penetration of
BT-474 cancer cells into adjacent normal tissues (Figure 7A).
Although injection of rCCL18 into BT-474 and MDA-MB-231
xenografts did not obviously change the primary tumor size (Fig-
ure S7A), it increased the number of mice with lung and liver
metastases (Table S4), the average lung weight (Figure 7B),
and the number of metastatic nodules in the livers (Figures
S7B and S7C). When the mice were xenografted with BT-474
and MDA-MB-231 cells that stably express luciferase, lumines-
cence imaging for the harvested lungs and livers demonstrated
that the severity of lung and liver metastasis was promoted by
treatment with rCCL18 (Figure 7C). Hematoxylin and eosin stain-
ing (H&E) also showed that rCCL18 injection led tomoremassive
metastasis in the lungs and livers of the mice bearing BT-474 or
MDA-MB-231 xenografts as compared with PBS or rCCL20
injection (Figures 7D and 7F). Quantification of human HPRT
mRNA also demonstrated that rCCL18 increased the number
of metastatic breast cancer cells in both lungs and livers by
5.5- and 3.2-fold, respectively, in the BT-474 xenografted
mice, and by 2.7- and 2.6-fold, respectively, in the MDA-MB-
231 xenografted mice as compared with PBS injection (Figures
7E and 7G). More importantly, Kaplan-Meier analysis demon-
strated that rCCL18 injection reduced the survival of the mice
xenografted with BT-474 or MDA-MB-231 cells compared with
PBS or rCCL20 injection (Figure 7H). Collectively, these data
suggest that CCL18 enhances lung and liver metastases of
breast cancer xenografts.
Furthermore, rCCL18 failed to enhance the vascular invasion
and peritumoral penetration of BT-474 xenografts infected with
lenti-PITPNM3-shRNA, but not with lenti-GFP-shRNA (Fig-
ure 7A). Silencing PITPNM3 also alleviated the promoting effect
of rCCL18 on lung and livermetastases of BT-474 andMDA-MB-
231 xenografts (Table S4; Figures 7 B–7G) and abrogated
CCL18-induced reduction in mouse survival and body weight
(Figures 7H and 7I). These results suggest that CCL18 promotes
invasion and metastasis of breast cancers in vivo in a PITPNM3-
dependent manner.
To further evaluate whether CCL18 promotes in vivo metas-
tasis by enhancing ECM adherence via FAK activation and integ-
rin clustering, we performed intratumor injection of synthetic
FAK-siRNA or integrin-b1-siRNA in BT474 xenografts 48 hr prior
to each episode of rCCL18 administration. Although injection of
FAK-siRNA or integrin-b1-siRNA did not obviously alter primary
tumor size (Figure S7D), transient silencing of FAK or integrin-b1
significantly alleviated CCL18-promotingmetastasis to the lungs
and the livers (Figures S7E–S7I), and prolonged mouse survival
upon CCL18 treatment (Figure S7J). Similar results were
obtained in the NOD/SCID mice xenografted with MDA-MB-
231 cells (data not shown). Therefore, CCL18-induced ECM
adherence of breast cancer cells ultimately contributes to
in vivo metastasis.
DISCUSSION
TAM-featured inflammation is known as the seventh hallmark of
cancer’’ (Condeelis and Pollard, 2006; Pollard, 2004). Although
M1 macrophage is linked with tumoricidal activity, M2 macro-
phage is associated with cancer progression and metastasis
Figure 6. CCL18 Enhances Fibronectin Adherence and Invasiveness of Breast Epithelial Cells via Interacting with PITPNM3
(A) Adherence assay for MDA-MB-231 cells that were mock transfected, or transfected with GFP-siRNA or either of the PITPNM3-siRNAs, and were treated with
PBS or rCCL18 at 20 ng/ml.
(B) Boyden chamber assay for the MDA-MB-231 cells that were treated as in (A). Bars correspond to mean ± SD. ***p < 0.001 versus untransfected control (Un).
(C) Western blotting of MDA-MB-231 cells treated with PBS, rCCL20, or rCCL18 with or without transfection of GFP-siRNA or either of the PITPNM3-siRNAs for
the expression of the phosphorylated and total proteins of Pyk2, FAK, and Src; b-actin was used as a loading control.
(D and E) Confocal microscopy of integrin a5b1 staining of PBS-treated or rCCL18-treated MDA-MB-231 cells that were untransfected (D), or mock transfected,
transfected with PITPNM3-siRNAs, FAK-siRNAs, integrin-b1-siRNAs, or GFP-siRNA (E).
(F) Adherence assays for MDA-MB-231 cells that were untransfected, mock transfected, or transfected with GFP-siRNA or either of the FAK-siRNAs or integrin-
b1-siRNAs in the presence or absence of rCCL18 at 20 ng/ml.
(G) Boyden chamber assay for MDA-MB-231 cells that were untransfected (Un), mock transfected, or transfected with FAK-siRNAs, integrin-b1-siRNAs,
or GFP-siRNA, followed by treatment for 8 hr with PBS or rCCL18. Bars correspond tomean ± SD. *p < 0.05 and ***p < 0.001 as compared with the untransfected
cells.
See also Figure S6.
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Figure 7. CCL18 Promotes Lung and Liver Metastasis of Breast Cancer Xenografts via PITPNM3
(A) Microscopic images of H&E for breast cancer xenografts demonstrating the presence or absence of margin invasion (upper) and vascular invasion (lower) of
BT-474 tumors.
(B) Wet lung weight in tumor-bearing mice. Bars correspond to mean ± SD.
(C) Luminal images of the lungs (left) and livers (right) of tumor-bearing mice.
(D and F) H&E of the lungs (D) and livers (F) in the mice-bearing BT-474 (upper) and MDA-MB-231 (lower) xenografts.
(E and G) Expression of human HPRT mRNA relative to mouse 18S rRNA in the lungs (E) and livers (G) of the tumor-bearing mice. Data are normalized to
PBS-treated mice.
(H) Kaplan-Meier survival curve for the mice-bearing BT-474 (left) and MDA-MB-231 xenografts (right).
(I) Body weight of tumor-bearing mice. Bars correspond to mean ± SD. *p < 0.05, **p < 0.01, and ***p < 0.001 as compared with PBS-treated mice.
See also Figure S7,and Tables S4 and S5.
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breast TAMs are primarily a polarized M2 macrophage popula-
tion (DeNardo et al., 2009). Here, we showed that CCL18, a char-
acteristic C-C chemokine released by M2 macrophages, is552 Cancer Cell 19, 541–555, April 12, 2011 ª2011 Elsevier Inc.abundantly expressed in breast TAMs and correlates with the
metastasis and poor prognosis of patients with breast cancer.
Chemokines exert their effects by binding to specific trans-
membrane receptors, which are members of a large family
Cancer Cell
CCL18 from TAM Promotes Breast Cancer Metastasisof G protein-coupled receptors (GPCRs). Currently, 22 chemo-
kine receptors have been characterized to mediate the effects
of more than 47 known chemokines, with overlapping specific-
ities for one another (Jin et al., 2008). Recent studies have
demonstrated that tumor cells also express restricted and
specific patterns of chemoreceptors (Lazennec and Richmond,
2010; Vandercappellen et al., 2008). Although CCL18-induced
chemotaxis in naive T cells was suggested to be mediated by
GPCR (Adema et al., 1997), the cognate receptor and down-
stream-signaling pathways of CCL18 remained unknown. Our
data reveal that CCL18 specifically binds to PITPNM3 at the
cellular membrane of breast cancer cells to exert its biological
activities. Several lines of our evidence in HEK293 cells stably
transfected with PITPNM3 support the conclusion that PITPNM3
is a functional receptor for CCL18. These were obtained from
functional assays that had traditionally been used to characterize
chemokine receptors (Murdoch and Finn, 2000), including high-
affinity binding of CCL18 to PITPNM3, dose-dependent mobili-
zation of [Ca2+]i, activation of the mediators in the [Ca
2+]
signaling pathway, and directional migration of PITPNM3 trans-
fectants in response to CCL18. Furthermore, our data demon-
strated that PITPNM3 served as an essential CCL18 receptor
in breast cancer cells to mediate CCL18 effects of promoting
invasion and metastasis.
PITPNM3, also named Nir1, was shown to be expressed in
human retina, brain, spleen, and ovary (Lev et al., 1999). Our
study demonstrated that PITPNM3 is abundantly expressed in
breast cancer cells. In contrast to other members in the family
of the PYK2-binding proteins, such as Nir2 and Nir3 that are
associated with endoplasmic reticula and Golgi complex
(Lev, 2004; Amarilio et al., 2005), PITPNM3/Nir1 is localized at
the plasma membrane of breast cancer cells and HEK293 trans-
fectants. PITPNM3 expression is essential to CCL18-induced
calcium influx and chemotaxis, which could be completely abro-
gated by pretreatment with a GPCR pathway inhibitor, pertussis
toxin (PTX) (data not shown). These results suggest that
PITPNM3 is a GPCR. However, previously identified chemokine
receptors are seven-transmembrane GPCRs, and PITPNM3was
suggested as a putative six-transmembrane protein because its
primary structures harbor six hydrophobic stretches (Lev et al.,
1999). Nevertheless, it has been reported that truncated version
of five-transmembrane proteins is sufficient to exert GPCR
function (Ling et al., 1999). In light of the large structural diversity
and lack of consensusmotif at the intracellular regions of GPCRs
(Wong, 2003), conformation at the intracellular region of
PITPNM3 may determine G protein selection and activation for
downstream intracellular signaling events, which needs further
study.
Our findings of extensive PITPNM3 expression and its func-
tional role in breast cancer cells support the correlation of
CCL18-expressing TAM count and patient prognosis because
more CCL18 produced by TAMs may exert a stronger metas-
tasis-promoting effect on breast cancer cells expressing
PITPNM3. In contrast, PITPNM3 is barely detected in gastric
cancer cells, and CCL18+ TAMs are positively associated with
patient survival in gastric cancer (Leung et al., 2004). The
disparity of PITPNM3 expression between breast and gastric
cancers may suggest that gastric cancer cells do not respond
to CCL18 in the same way as breast cancer cells, which mayexplain the distinct clinical outcomes of the two malignancies
associated with CCL18+ TAM counts.
It has been shown that ECM adherence of tumor cells is a key
biological process for epithelial tumor cells to increase invasive-
ness (Thiery et al., 2009). CCL18 triggers integrin clustering and
ECM adherence of the tumor cells, which eventually contribute
to enhanced invasiveness and metastasis. The molecular
mechanism responsible for these phenomena is activating phos-
phorylation of FAK in the FAC mediated by PITPNM3, which is
independent of integrin expression. It has been noted that
Pyk2, a key component of the FAC, interacts with PITPNM3
(Lev et al., 1999), and Pyk2 is associated with other NRTKs at
the FAC, such as Src and FAK, which may form the basis of
FAK activation and ECM adherence when PITPNM3 is ligated
with CCL18. In the stroma of invasive carcinomas, TAMs
produce a variety of proteases, including uPA and various matrix
metalloproteinases, to degrade the basement membrane and
the surrounding ECM, leading to the exposure of the fibronectin
molecules to tumor cells (Pollard, 2004). By enhancing the adhe-
sion of the dissociated breast cancer cells to the exposed fibro-
nectin, CCL18 may assist cancer cells to penetrate and migrate
through the tumor stroma and ultimately egress into lymphatic or
blood vessels for regional or distal metastasis (Thiery et al.,
2009).
In summary our study shows that PITPNM3 is a functional
receptor for CCL18, an important TAM-derived cytokine, in
promoting breast cancer metastasis. Other TAM-derived
chemokines or growth factors (Coussens et al., 2000; Dirkx
et al., 2006; Goswami et al., 2005; Leek et al., 2002) may also
contribute via other signaling pathways because suppression
of CCL18 or PITPNM3 did not completely block breast cancer
metastasis elicited by TAMs. Further studies are needed to eval-
uate whether the cytokine repertoire released by TAMs can be
manipulated to inhibit tumor progression.EXPERIMENTAL PROCEDURES
Patients and Tissue Samples
Primary ductal carcinomas of the breasts were obtained from 562 female
patients (median age 48.5 years, range 21–79) at the No. 2 Affiliated Hospital,
Sun-Yat-Sen University, from January 2002 to October 2007. Pathological
diagnosis, as well as ER and Her2 status, was verified by two different
pathologists. Patients with invasive carcinomas, other than DCIS, underwent
six cycles of postoperative adjuvant chemotherapy with FAC regimen
(5-fluorouracil 500 mg/m2, doxorubicin 50 mg/m2, and cyclophosphamide
500 mg/m2). Subsequently, patients with ER+ tumors underwent endocrine
therapy according toNCCNguideline. Distal metastasis was not found in these
patients upon diagnosis but was identified in 105 cases during postoperative
follow-up. Additionally, benign breast tissue samples were collected from
61 cases of cystic fibrosis of the breast with or without atypical epithelial
hyperplasia. All samples were collected with informed consent according to
the Internal Review and the Ethics Boards of the Sun-Yat-Sen Memorial
Hospital of Sun-Yat-Sen University.
Cell Cultures and Treatment
MDA-MB-231, MDA-MB-435s, BT-474, SKBR3, and MCF-7 breast cancer
cells, MCF-10A breast epithelial cells, SNU16 and SGC7901 gastric cancer
cells, and HEK293 embryonic kidney cells were obtained from American
Type Culture Collection (ATCC) and grown according to standard protocols.
PBMs from patients with breast cancer or healthy donors were isolated by
density-gradient centrifugation using Ficoll-Hypaque (Pharmacia). Primary
breast cancer cells were isolated from eight cases of freshly removed tumorCancer Cell 19, 541–555, April 12, 2011 ª2011 Elsevier Inc. 553
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instruction, and TAMswere isolated from47 fresh tumor sampleswith a Percoll
Density Gradient Centrifugation kit (Pharmacia).
Affinity Purification of CCL18-Interacting Proteins
MDA-MB-231 cells were grown to 75% confluence followed by treatment for
60min with 20 ng/ml rCCL18 in serum-free medium.Membrane proteins of the
treated cells were extracted using a ProteoExtract Native Membrane Protein
Extraction Kit (M-PEK Kit; Calbiochem) according to manufacturer’s instruc-
tion. As a control, 0.1% sodium dodecyl sulfate (SDS) was added into the solu-
bilized extracts to disrupt the interaction between rCCL18 and the unknown
receptor, and SDS was then removed by precipitation using an SDS-Out
Precipitation Kit (Pierce). The solubilized extracts were then incubated with
30 ml of protein A/G beads coupled to a mouse anti-human monoclonal
CCL18 antibody (R&D) at room temperature for 2 hr. The beads were then
washed with lysis buffer three times, followed by boiling in 13 sample buffer.
The immunoprecipitates were resolved on an SDS-PAGE denaturing gel, visu-
alized by Coomassie blue, and the protein band of interest was removed for
mass spectrometric analysis.
Tumor Xenografts
Female NOD/LtSz-scid/scid (NOD/SCID) mice were bred and maintained
under defined conditions at the Animal Experiment Center of Sun-Yat-Sen
University, and all procedures were approved by the Animal Care and Use
Committee of Sun-Yat-Sen University and conformed to the legal mandates
and national guidelines for the care and maintenance of laboratory animals.
Breast cancer MDA-MB-231-luc (2 3 106) and BT-474 cells-luc (5 3 106)
that were uninfected or infected with lentivirus carrying GFP-shRNA or
PITPNM3-shRNA were inoculated into the mammary fat pads of the mice
(n = 8/group). When the xenografts were palpable (around 0.5 cm in diameter),
intratumor injection of PBS, rCCL20, or rCCL18 at 0.1 mg/kg was performed
biweekly for 4 consecutive weeks. In some experiments, intratumor injection
of PBS, lipofectamine (5 ml) alone or in complex with integrin-b1-siRNA,
FAK-siRNA, or GFP-siRNA at 2 mg/kg was performed 48 hr prior to CCL18
injection. Tumor growth was evaluated by monitoring tumor volume (TV =
length 3 width2 3 0.5) every 3 days for 8 weeks. The animals were sacrificed
when the xenografts reached 1.5 cm in diameter, and tumor xenografts, lungs,
and livers of the mice were harvested for further evaluation. Cryosections (4
mm) of the harvested organs were H&E for histological assessment, and total
RNA was extracted for qRT-PCR analysis of human HPRT mRNA expression.
The lungs and livers of the animals bearing breast tumor xenografts that stably
express luciferase were analyzed by IVIS Lumina Imaging System (Xenogen).
Statistics
All statistical analyseswere done using SPSS forWindows version 13.0 (SPSS,
Chicago). Student’s t test and one-way ANOVA were used to correlate serum
CCL18 level with cancer metastasis, whereas chi-square test was applied to
analyze the relationship between CCL18+ TAM counts and clinicopathological
status. Kaplan-Meier survival curves were plotted, and log rank test was done.
The significance of various variables for survival was analyzed by the Cox
proportional hazards model in a multivariate analysis. All experiments for cell
cultures were performed independently for at least five times and in triplicate
for each time. A p value <0.05 in all cases was considered statistically
significant.
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